TABLE 1.
Reactivity of PBMC from RHD patients and controls against relevant M5 peptides
| Peptide | Result for PBMC from:
|
||||||||
|---|---|---|---|---|---|---|---|---|---|
| Patients with severe RHD (n = 37)
|
Patients with mild RHD (n = 33)
|
Health controls (n = 35)
|
|||||||
| % Reactivity | SIa | SE | % Reactivity | SI | SE | % Reactivity | SI | SE | |
| M5(1–20) | 35.1b | 4.8 | 0.67 | 27.3 | 3.4 | 0.26 | 8.6 | 2.8 | 0.15 |
| M5(11–25) | 21.6 | 5.4 | 1.01 | 36.4c | 4.0 | 0.60 | 8.6 | 2.8 | 0.06 |
| M5(81–96) | 46.0d | 4.4 | 0.45 | 27.3 | 4.3 | 0.49 | 8.6 | 3.3 | 0.29 |
| M5(81–103) | 27.0 | 4.2 | 1.20 | 24.2 | 4.4 | 1.30 | 11.4 | 3.3 | 0.40 |
| M5(91–103) | 24.3b | 3.8 | 0.48 | 9.1 | 4.1 | 0.35 | 3.0 | 2.9f | |
| M5(125–139) | 16.2 | 3.9 | 0.81 | 24.2b | 3.6 | 0.39 | 3.0 | 2.6f | |
| M5(163–177) | 24.3e | 5.5 | 1.26 | 24.2e | 3.6 | 0.37 | 5.7 | 3.5 | 0.26 |
a
SI, mean of positive SI values.
b
Significant results compared healthy controls (P = 0.01).
c
Significant in comparison with healthy controls (P = 0.008).
d
Significant in comparison with healthy controls (P = 0.0005).
e
Significant in comparison with healthy controls (P = 0.04).
f
Positive SI values of an individual.